Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: Assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy

Memorias do Instituto Oswaldo Cruz

Volumn 100, Issue 1, 2005, Pages 73-78

  Couto Fernandez, J C ^a   Silva De Jesus, C ^a   Veloso, V G ^b   Rachid, M ^c   Gracie, R S G ^d   Chequer Fernandez, S L ^a   Oliveira, S M ^e   Arakaki Sanchez, D ^e   Chequer, P J N ^e   Morgado, M G ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Inst Pesquisa Clin Hosp E   (Brazil)

^c Secretaria Estadual de Saude   (Brazil)

^d Lab G   (Brazil)

^e MINISTÉRIO DA SAÚDE   (Brazil)

Author keywords

Brazil; Genotyping; Human immunodeficiency virus type 1; Resistance; Subtypes

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR;

BLOOD SAMPLING; CONFERENCE PAPER; CONTROLLED STUDY; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RESISTANCE; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MUTATION RATE; MUTATIONAL ANALYSIS; PATIENT MONITORING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT FAILURE; VIRUS IDENTIFICATION; VIRUS RECOMBINANT; VIRUS RESISTANCE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 20144378739     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02762005000100014     Document Type: Conference Paper

References (27)

1. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC 2000. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beim Community Programs for Clinical Research on AIDS. AIDS 16: F83-93.
2. Bongertz V, Bou-Habib DC, Brigido LF, Caseiro M, Chequer, PJN, Couto-Fernandez JC, Ferreira PC, Galvão-Castro B, Greco D, Guimarães ML, Linhares de Carvalho MI. Morgado MG, Oliveira CA, Osmanov S, Ramos CA, Rossini M, Sabino E, Tanuri A, Ueda M 2000. HIV-1 diversity in Brazil: genetic, biologic and immunologic characterization of HIV-1 strains in three potential vaccine evaluation sites. Brazilian Network for HIV Isolation and Characterization. J AIDS Hum Retroviruses 23: 184-93.
3. Brindeiro R, Diaz, R, Sabino E, Morgado M, Pires I, L Brígido L, Dantas M, Barreira D, Teixeira P, Tanuri A and the Brazilian Network for Drug Resistance Surveillance 2003. Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS 17: 1063-1069.
4. Boletim Epidemiológico 2003. Programa Nacional de DST e AIDS, Ministério da Saúde - MS-PNDST/AIDS, Ano XVII no. 01, 01 a 52 semanas epidemiológicas janeiro a dezembro (www.aids.gov.br/ boletimepidemiologico).
5. Caride E, Brindeiro R, Hertogs K, Lader B, Dehertogh P, Machado E, Moraes-de-Sá CA, Eyer-Silva WA, Sion FS, Passioni LF, Menezes JA, Calazans AR, Tanuri A 2000. Drug-resistance reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type 1 found in brazilian patients failing HAART. Virology 15: 107-115.
6. Cohen NJ, Oram R, Elsen C, Englund JA 2002. Response to changes in antiretroviral therapy after genotyping in human immunodeficiency virus-infected children. J Pediatr Infect Dis 21: 647-53.
7. D'Aquila RT, Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD, International AIDS Society-USA 2002. Drug resistance mutations in HIV-1. Top HIV Med 10: 21-25.
8. Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Munoz A, Multicenter AIDS Cohort Study 2001. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 15: 347-55.
9. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM, Dellamonica P 1999. Drug-resistance genotyping in HIV-1 therapy: the Viradapt randomised controlled trial. Lancet 353: 2195-2199.
10. Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP, Richman DD 2000. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 283: 229-234.
11. Hirsch MS, Richman DD 2000. The role of genotypic resistance testing in selecting therapy for HIV. JAMA 284: 1649-1650.
12. Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Áquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DD 2003. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1 2003. Recommendations of an International AIDS Society-USA panel. Clin Infect Dis 37: 113-128.
13. Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, Nakiyingi J, Rutebemberwa A, Morgan D, Weber J, Gilks C, Whitworth J 2002. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 185: 1244-1250.
14. Kanki PJ, Hamel DJ, Sankale JL, Hsieh CC, Thior I, Barin F, Woodcok AS, Gueye-Ndiaye A, Zhang E, Montano M, Siby T, Marlink R, Ndoye I, Essex ME, Mboup S 1999. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 179: 68-73.
15. Kuiken C, Foley B, Freed E, Hahn B, Marx P, McCutchan F, Mellors J, Wolinsky S, Korber B 2002. HIV Sequence Compendium, Los Alamos National Laboratory, US.
16. Limonad E 1996. Os Lugares da Urbanização - O Caso do Interior Fluminense, PhD Thesis, USP, São Paulo.
17. Marins JR, Jamal LF, Chen SY, Barros MB, Hudes ES, Barbosa AA, Chequer P, Teixeira PR, Hearst N 2003. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS 17: 1675-1682.
18. Mansky LM 1998. Retrovirus mutation rates and their role in genetic variation. J Gen Virol 79: 1337-1345.
19. Morgado MG, Guimarães ML, Neves Jr I, Veloso dos Santos VG, Linhares-de-Carvalho MI, Bastos FI, Castilho EA, Galvão-Castro B, Bongertz V, HEC AIDS Clin Res Group 1998. Molecular epidemiology of HIV in Brazil: polymorphism of the antigenically distinct subtype B isolates. Mem Inst Oswaldo Cruz 93: 383-386.
20. Osmanov S, Pattou C, Walker N, Schwardlander B, Esparza J, WHO-UNAIDS Network for HIV Isolation and Characterization 2002. Estimated global distribution and regional spread of HIV-1 genetic subtypes in 2000. J Aquir Immune Defic Synd 29: 184-190.
21. Ray SC 1999. Simplot for Windows version 2.5 (Distributed by the author, http//w.w.w.med.jhu.edu/depmed/sry/down-load/).
22. Simoni JM, Frick PA, Pantalone DW, Turner BJ 2003. Antiretroviral adherence interpretations: A review of current literature of ongoing studies. Topics in HIV Medicine, IAS-Drug resistance mutations group 11: 185-199.
23. Shafer RW, Winters MA, Palmer S, Merigan TC 1998. Multiple concurrent reverse transcriptase and protease mutations multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 128: 906-911.
24. Tanuri A, Caride E, Dantas MC, Morgado MG, Mello DL, Borges S, Tavares M, Ferreira SB, Santoro-Lopes G, Martins CR, Esteves AL, Diaz RS, Andreo SM, Ferreira LA, Rodrigues R, Reuter T, Cavalcanti AM, de Oliveira SM, de Barbosa HB, Teixeira PR, Chequer PN 2002. Prevalence of mutations related to HIV-1 antiretroviral resistance in Brazilian patients failing HAART. J Clin Virol 25: 39-46.
25. Vella S 2002. Antiretroviral drug resistance and HIV/AIDS in the developing world. J HIV Ther 7: 53-55.
26. Vella S, Palmisano L 2000. Antiviral therapy: state of the HAART. Antiviral Res 45: 1-7.
27. Wainberg MA 2004. The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev Anti Infect Ther 2: 147-51.